<DOC>
	<DOC>NCT00782353</DOC>
	<brief_summary>The purpose of this study is to investigate the safety, tolerability, and antiviral activity of ANA598 in patients with genotype-1 chronic hepatitis C infection.</brief_summary>
	<brief_title>Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection</brief_title>
	<detailed_description>The safety, tolerability and antiviral activity of ANA598, administered orally twice daily for 3 days, will be compared to placebo in treatment-naïve subjects chronically infected with HCV genotype 1 infection. Thirty (30) subjects will be randomized to one of three cohorts described above. The ten patients in each cohort will be randomized 8 active: 2 placebo. At least 5 subjects with genotype 1a and 5 subjects with genotype 1b will be enrolled within each cohort.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Male or female, ages 18 to 65 years Documented chronic HCV infection, genotype 1a or 1b Treatmentnaïve BMI = 18 35 kg/m2 Female patients who are pregnant or breastfeeding Previous treatment for HCV infection HIV or HBV positive Evidence of cirrhosis on previous liver biopsy or on previous imaging studies History of any other known cause of liver disease;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HCV</keyword>
</DOC>